What is Sensorium Therapeutics?
Sensorium Therapeutics is a clinical-stage biotechnology company leveraging artificial intelligence for the discovery of novel, nature-inspired therapeutics. The company's focus areas include critical conditions such as anxiety, epilepsy, and Alzheimer's disease, positioning it at the forefront of neurodegenerative and psychiatric disorder treatment innovation. The recent capital infusion signals strong market confidence in its AI-driven discovery platform and its potential to address unmet medical needs.
How much funding has Sensorium Therapeutics raised?
Sensorium Therapeutics has raised a total of $55M across 2 funding rounds:
Series A
$30M
Series A
$25M
Series A (2022): $30M with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and Santé Ventures
Series A (2025): $25M led by Mission BioCapital, Mockingbird Credit Partners, Hatteras Venture Partners, and Dolby Family Ventures
Key Investors in Sensorium Therapeutics
Route 66 Ventures
Route 66 Ventures is a private investment firm focused on helping entrepreneurs shape the financial services landscape of tomorrow by providing Venture Capital and Credit solutions to emerging financial technology and services companies.
CU Healthcare Innovation Fund
CU Healthcare Innovation Fund is a strategic venture capital firm affiliated with the University of Colorado Anschutz Medical Campus, focused on advancing healthcare innovation and utilizing its extensive ecosystem to assist portfolio companies.
Santé Ventures
Santé Ventures is a privately held investment firm that focuses on innovative healthcare and technology companies, managing over $1 billion in capital and primarily investing in the Biotech, Medtech, and Healthtech sectors.
What's next for Sensorium Therapeutics?
With this substantial financial backing, Sensorium Therapeutics is poised to accelerate its clinical development pipeline and further enhance its AI-driven discovery engine. The strategic investment is expected to fuel research and development efforts, potentially leading to expanded clinical trials and the advancement of its lead drug candidates. This funding round signifies a pivotal moment for the company, enabling it to scale its operations and solidify its position in the competitive biotech landscape, aiming to bring its groundbreaking treatments to patients.
See full Sensorium Therapeutics company page
